Jazz Pharmaceuticals (NASDAQ:JAZZ) CAO Patricia Carr Sells 1,287 Shares of Stock

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) CAO Patricia Carr sold 1,287 shares of the stock in a transaction that occurred on Monday, March 9th. The shares were sold at an average price of $182.94, for a total transaction of $235,443.78. Following the completion of the sale, the chief accounting officer directly owned 6,512 shares of the company’s stock, valued at $1,191,305.28. This trade represents a 16.50% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Patricia Carr also recently made the following trade(s):

• On Friday, February 27th, Patricia Carr sold 1,117 shares of Jazz Pharmaceuticals stock. The stock was sold at an average price of $190.91, for a total transaction of $213,246.47.
• On Thursday, February 26th, Patricia Carr sold 1,253 shares of Jazz Pharmaceuticals stock. The stock was sold at an average price of $194.11, for a total transaction of $243,219.83.

Jazz Pharmaceuticals Stock Performance

NASDAQ:JAZZ opened at $185.40 on Tuesday. The company has a debt-to-equity ratio of 1.00, a current ratio of 1.86 and a quick ratio of 1.67. The firm has a 50-day moving average of $171.41 and a two-hundred day moving average of $154.78. The stock has a market cap of $11.41 billion, a P/E ratio of -31.06, a PEG ratio of 0.33 and a beta of 0.22. Jazz Pharmaceuticals PLC has a 1-year low of $95.49 and a 1-year high of $198.00.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last announced its earnings results on Tuesday, February 24th. The specialty pharmaceutical company reported $6.64 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $6.49 by $0.15. Jazz Pharmaceuticals had a positive return on equity of 6.87% and a negative net margin of 8.35%.The business had revenue of $1.20 billion for the quarter, compared to analyst estimates of $1.17 billion. During the same period in the previous year, the company earned $6.51 earnings per share. The company’s revenue for the quarter was up 8.1% compared to the same quarter last year. On average, research analysts expect that Jazz Pharmaceuticals PLC will post 16.96 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on JAZZ. Morgan Stanley upped their target price on Jazz Pharmaceuticals from $225.00 to $226.00 and gave the company an “overweight” rating in a research report on Wednesday, February 25th. Barclays restated an “overweight” rating and issued a $224.00 price target on shares of Jazz Pharmaceuticals in a research note on Monday. Piper Sandler reaffirmed an “overweight” rating and issued a $219.00 price target (up from $147.00) on shares of Jazz Pharmaceuticals in a report on Wednesday, December 10th. Weiss Ratings reiterated a “sell (d+)” rating on shares of Jazz Pharmaceuticals in a research note on Monday, December 29th. Finally, Wells Fargo & Company raised their price objective on shares of Jazz Pharmaceuticals from $235.00 to $250.00 and gave the stock an “overweight” rating in a report on Wednesday, February 25th. Thirteen investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Jazz Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average price target of $214.38.

Institutional Investors Weigh In On Jazz Pharmaceuticals

Several large investors have recently added to or reduced their stakes in the stock. Corient Private Wealth LLC lifted its stake in Jazz Pharmaceuticals by 91.1% in the fourth quarter. Corient Private Wealth LLC now owns 10,200 shares of the specialty pharmaceutical company’s stock valued at $1,734,000 after buying an additional 4,863 shares during the last quarter. DGS Capital Management LLC acquired a new stake in shares of Jazz Pharmaceuticals in the 4th quarter worth about $260,000. Pacer Advisors Inc. increased its holdings in shares of Jazz Pharmaceuticals by 19.8% in the 4th quarter. Pacer Advisors Inc. now owns 647,084 shares of the specialty pharmaceutical company’s stock worth $110,004,000 after acquiring an additional 107,144 shares during the period. Kera Capital Partners Inc. bought a new stake in Jazz Pharmaceuticals in the 4th quarter valued at about $336,000. Finally, Dean Capital Management lifted its position in Jazz Pharmaceuticals by 3.2% in the 4th quarter. Dean Capital Management now owns 21,158 shares of the specialty pharmaceutical company’s stock valued at $3,597,000 after purchasing an additional 654 shares during the last quarter. 89.14% of the stock is owned by institutional investors and hedge funds.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.